BRPI0210076B8 - preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato - Google Patents
preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinatoInfo
- Publication number
- BRPI0210076B8 BRPI0210076B8 BRPI0210076A BRPI0210076B8 BR PI0210076 B8 BRPI0210076 B8 BR PI0210076B8 BR PI0210076 A BRPI0210076 A BR PI0210076A BR PI0210076 B8 BRPI0210076 B8 BR PI0210076B8
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- tocopherol
- alpha
- influenza virus
- influenza
- Prior art date
Links
- 101710154606 Hemagglutinin Proteins 0.000 title abstract 5
- 101710093908 Outer capsid protein VP4 Proteins 0.000 title abstract 5
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 title abstract 5
- 101710176177 Protein A56 Proteins 0.000 title abstract 5
- 239000000185 hemagglutinin Substances 0.000 title abstract 5
- 241000712461 unidentified influenza virus Species 0.000 title abstract 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 229940087168 alpha tocopherol Drugs 0.000 title abstract 2
- 229960003971 influenza vaccine Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 title abstract 2
- 229960000984 tocofersolan Drugs 0.000 title abstract 2
- 239000002076 α-tocopherol Substances 0.000 title abstract 2
- 235000004835 α-tocopherol Nutrition 0.000 title abstract 2
- 206010022000 influenza Diseases 0.000 abstract 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 abstract 2
- 229960004906 thiomersal Drugs 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000693 micelle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000011732 tocopherol Substances 0.000 abstract 1
- 229960001295 tocopherol Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0113083A GB0113083D0 (en) | 2001-05-30 | 2001-05-30 | Novel compounds |
| GB0113083.0 | 2001-05-30 | ||
| GB0204116.8 | 2002-02-21 | ||
| GB0204116A GB0204116D0 (en) | 2002-02-21 | 2002-02-21 | Novel vaccine composition |
| PCT/EP2002/005883 WO2002097072A2 (en) | 2001-05-30 | 2002-05-29 | Influenza vaccine composition |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BR0210076A BR0210076A (pt) | 2004-06-22 |
| BRPI0210076A8 BRPI0210076A8 (pt) | 2017-05-23 |
| BRPI0210076B1 BRPI0210076B1 (pt) | 2020-01-07 |
| BRPI0210076B8 true BRPI0210076B8 (pt) | 2021-05-25 |
Family
ID=30445235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0210076 BRPI0210076B8 (pt) | 2001-05-30 | 2002-05-29 | preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7316813B2 (https=) |
| EP (3) | EP2495314A1 (https=) |
| JP (1) | JP4074582B2 (https=) |
| KR (1) | KR100871021B1 (https=) |
| CN (2) | CN1279165C (https=) |
| AR (1) | AR036039A1 (https=) |
| AT (1) | ATE420159T1 (https=) |
| AU (2) | AU2006200742C9 (https=) |
| BR (1) | BRPI0210076B8 (https=) |
| CA (1) | CA2448208C (https=) |
| CO (1) | CO5540349A2 (https=) |
| CY (1) | CY1108930T1 (https=) |
| CZ (1) | CZ298697B6 (https=) |
| DE (1) | DE60230760D1 (https=) |
| DK (1) | DK1407008T3 (https=) |
| ES (1) | ES2318020T3 (https=) |
| FR (1) | FR13C0072I1 (https=) |
| HU (1) | HU229368B1 (https=) |
| IL (2) | IL158931A (https=) |
| MX (1) | MXPA03010944A (https=) |
| MY (1) | MY134424A (https=) |
| NO (1) | NO335212B1 (https=) |
| NZ (1) | NZ529755A (https=) |
| PL (1) | PL206435B1 (https=) |
| PT (1) | PT1407008E (https=) |
| SI (1) | SI1407008T1 (https=) |
| TW (1) | TWI228420B (https=) |
| WO (1) | WO2002097072A2 (https=) |
| ZA (1) | ZA200309250B (https=) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200200776T2 (tr) * | 1999-09-24 | 2002-06-21 | Smithkline Beecham Biologicals S.A. | Burun içi grip virüsü aşısı. |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| US20100221284A1 (en) * | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
| TWI228420B (en) * | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| US20060110406A1 (en) | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
| US7262045B2 (en) | 2003-02-25 | 2007-08-28 | Medimmune Vaccines, Inc. | Methods of producing influenza vaccine compositions |
| JP2008512443A (ja) | 2004-09-09 | 2008-04-24 | カイロン ベーリング ゲーエムベーハー アンド カンパニー | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
| JP5147405B2 (ja) * | 2004-10-06 | 2013-02-20 | メディミューン，エルエルシー | 冷蔵温度安定型インフルエンザワクチン組成物 |
| EP2923711A1 (en) * | 2004-11-03 | 2015-09-30 | Novartis Vaccines and Diagnostics, Inc. | Influenza vaccination |
| US9161905B2 (en) * | 2005-01-12 | 2015-10-20 | Ocular Research Of Boston, Inc. | Dry eye treatment |
| PT1861120T (pt) * | 2005-03-23 | 2016-08-18 | Glaxosmithkline Biologicals Sa | Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória |
| ATE526036T1 (de) * | 2005-08-02 | 2011-10-15 | Novartis Vaccines & Diagnostic | Reduzierung der interferenz zwischen ölhaltigen adjuvanzien und surfactanthaltigen antigenen |
| CA2627971A1 (en) | 2005-11-01 | 2007-05-10 | Novartis Vaccines And Diagnostics Gmbh & Co Kg. | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
| US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| WO2007052061A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
| US20090304742A1 (en) | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
| ES2420829T3 (es) | 2005-11-04 | 2013-08-27 | Novartis Vaccines And Diagnostics S.R.L. | Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular |
| EP1951298A1 (en) | 2005-11-04 | 2008-08-06 | Novartis Vaccines and Diagnostics S.r.l. | Adjuvanted influenza vaccines including cytokine-inducing agents |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| EP3753574A1 (en) | 2006-01-27 | 2020-12-23 | Seqirus UK Limited | Influenza vaccines containing hemagglutinin and matrix proteins |
| EP2004226A1 (en) * | 2006-03-24 | 2008-12-24 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Storage of influenza vaccines without refrigeration |
| DK2054431T3 (da) | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
| HRP20140488T1 (hr) | 2006-07-17 | 2014-07-04 | Glaxosmithkline Biologicals S.A. | Cjepivo protiv influence |
| PT2043682E (pt) | 2006-07-17 | 2014-07-11 | Glaxosmithkline Biolog Sa | Vacina da influenza |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| ES2536401T3 (es) | 2006-09-11 | 2015-05-25 | Novartis Ag | Fabricación de vacunas contra virus de la gripe sin usar huevos |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| PL2086582T3 (pl) | 2006-10-12 | 2013-04-30 | Glaxosmithkline Biologicals Sa | Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie |
| SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| US9452209B2 (en) | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
| EA201070066A1 (ru) | 2007-06-27 | 2010-06-30 | Новартис Аг | Вакцины против гриппа с низким содержанием добавок |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| AU2008293504B2 (en) | 2007-08-27 | 2012-04-12 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
| AU2008293513B2 (en) * | 2007-08-28 | 2013-11-21 | Alachua Government Services, Inc. | Method for producing viral vaccines |
| CA2861667C (en) | 2007-10-01 | 2017-06-13 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system and methods of use |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| AU2008339631B2 (en) | 2007-12-24 | 2014-07-24 | Novartis Ag | Assays for adsorbed influenza vaccines |
| US8506966B2 (en) | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
| WO2009115917A2 (en) | 2008-03-18 | 2009-09-24 | Novartis Ag | Improvements in preparation of influenza virus vaccine antigens |
| SI2271360T1 (sl) | 2008-04-16 | 2015-12-31 | Glaxosmithkline Biologicals S.A. | Cepivo |
| JP2012507272A (ja) | 2008-11-05 | 2012-03-29 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規な方法 |
| SI2396030T1 (sl) | 2009-02-10 | 2015-12-31 | Novartis Ag | Sheme dajanja cepiva proti gripi za seve, povezane s pandemijo |
| AU2010212548A1 (en) * | 2009-02-10 | 2011-09-15 | Novartis Ag | Influenza vaccines with increased amounts of H3 antigen |
| WO2010092479A2 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with reduced amounts of squalene |
| FR2949344A1 (fr) | 2009-04-27 | 2011-03-04 | Novartis Ag | Vaccins de protection contre la grippe |
| EP2573184A1 (en) | 2009-05-21 | 2013-03-27 | Novartis AG | Reverse genetics using non-endogenous POL I promoters |
| US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| AU2010270722B2 (en) | 2009-07-06 | 2015-06-04 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| WO2011012999A1 (en) | 2009-07-31 | 2011-02-03 | Novartis Ag | Reverse genetics systems |
| CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
| CN102741399A (zh) | 2009-10-20 | 2012-10-17 | 诺华有限公司 | 用于病毒拯救的改良反向遗传方法 |
| GB0918830D0 (en) | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
| GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
| RS52748B (sr) | 2009-12-03 | 2013-08-30 | Novartis Ag | Cirkulacija komponenti tokom homogenizacije emulzija |
| EP2506832B1 (en) | 2009-12-03 | 2014-02-26 | Novartis AG | Hydrophilic filtration during manufacture of vaccine adjuvants |
| DE102009056871A1 (de) | 2009-12-03 | 2011-06-22 | Novartis AG, 4056 | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| DE102009056883B4 (de) | 2009-12-03 | 2012-08-16 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| JP5751678B2 (ja) | 2009-12-03 | 2015-07-22 | ノバルティス アーゲー | マイクロフルイダイゼーションのための相互作用チャンバおよび背圧チャンバの構成 |
| DE102009056884B4 (de) | 2009-12-03 | 2021-03-18 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| US20110305748A1 (en) | 2010-03-11 | 2011-12-15 | Immune Design, Corp. | Vaccines for Pandemic Influenza |
| WO2011138682A2 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Organic peroxide compounds for microorganism inactivation |
| SG185419A1 (en) | 2010-05-12 | 2012-12-28 | Novartis Ag | Improved methods for preparing squalene |
| AU2011254204B2 (en) | 2010-05-21 | 2015-08-20 | Seqirus UK Limited | Influenza virus reassortment method |
| CA2801151A1 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
| EP2575872B1 (en) | 2010-06-01 | 2020-08-19 | Seqirus UK Limited | Concentration of influenza vaccine antigens without lyophilization |
| WO2011154976A2 (en) | 2010-06-08 | 2011-12-15 | Panacea Biotec Limited | Improved influenza vaccine |
| MX342138B (es) | 2010-07-06 | 2016-09-14 | Variation Biotechnologies Inc | Composiciones y metodos para el tratamiento de influenza. |
| ES2531577T3 (es) | 2010-08-20 | 2015-03-17 | Novartis Ag | Conjuntos de agujas para la administración de vacuna soluble contra la gripe |
| US9657359B2 (en) | 2010-09-07 | 2017-05-23 | Novartis Ag | Generic assays for detection of mamalian reovirus |
| EP2632483A2 (en) | 2010-10-27 | 2013-09-04 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| CA2862864C (en) | 2011-01-13 | 2018-12-11 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| CA2862871C (en) | 2011-01-13 | 2020-09-22 | Variation Biotechnologies Inc. | Methods for preparing vesicles and formulations produced therefrom |
| JP5798356B2 (ja) * | 2011-04-06 | 2015-10-21 | 一般財団法人化学及血清療法研究所 | 新規インフルエンザワクチン安定化剤 |
| GB201216121D0 (en) | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
| CA2852857A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
| US20140328876A1 (en) | 2011-11-18 | 2014-11-06 | Variation Biotechnologies Inc. | Synthetic derivatives of mpl and uses thereof |
| US20140356399A1 (en) | 2012-01-12 | 2014-12-04 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
| WO2013112916A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| US20150079077A1 (en) | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
| EP2820126B1 (en) | 2012-03-02 | 2017-05-17 | Seqirus UK Limited | Influenza virus reassortment |
| GB201205189D0 (en) | 2012-03-23 | 2012-05-09 | Glaxosmithkline Biolog Sa | Novel medical use |
| US20130315955A1 (en) * | 2012-04-13 | 2013-11-28 | Protein Sciences Corporation | Stability and potency of hemagglutinin |
| WO2013182498A1 (en) | 2012-06-04 | 2013-12-12 | Novartis Ag | Improved safety testing |
| GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
| KR20150110494A (ko) | 2012-12-03 | 2015-10-02 | 노파르티스 아게 | 재배열 인플루엔자 a 바이러스 |
| EP2943221A1 (en) | 2013-01-10 | 2015-11-18 | Novartis AG | Influenza virus immunogenic compositions and uses thereof |
| HK1218511A1 (zh) | 2013-03-13 | 2017-02-24 | Novartis Ag | 乙型流感病毒重配 |
| EP2801372A3 (en) | 2013-05-10 | 2015-02-18 | Novartis AG | Avoiding narcolepsy risk in influenza vaccines |
| DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
| DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
| CA2914604A1 (en) | 2013-06-06 | 2014-12-11 | Novartis Ag | Influenza virus reassortment |
| CN104436157A (zh) | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | 流感疫苗和治疗 |
| JP6487850B2 (ja) | 2013-11-29 | 2019-03-20 | テルモ株式会社 | アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法 |
| ES2721306T3 (es) | 2014-12-02 | 2019-07-30 | Novartis Ag | Fabricación de composiciones que contienen tensioactivo |
| WO2016183292A1 (en) | 2015-05-14 | 2016-11-17 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
| HK1254344A1 (zh) | 2015-06-26 | 2019-07-19 | Seqirus UK Limited | 抗原匹配的流感疫苗 |
| HUE051783T2 (hu) | 2015-07-07 | 2021-03-29 | Seqirus Uk Ltd | Eljárás immunogén hemagglutinin mennyiségi meghatározására |
| WO2017167768A1 (en) | 2016-03-28 | 2017-10-05 | Glaxosmithkline Biologicals S.A. | Novel vaccine composition |
| GB201614799D0 (en) * | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
| IL271283B2 (en) | 2017-08-04 | 2024-04-01 | Syngenta Participations Ag | Methods and compositions for targeted genomic insertion |
| MX2020004151A (es) | 2017-10-30 | 2020-08-13 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos. |
| WO2020160080A1 (en) | 2019-01-30 | 2020-08-06 | Glaxosmithkline Llc | Oil/surfactant mixtures for self-emulsification |
| EP3959216A4 (en) | 2019-04-24 | 2023-01-11 | Icahn School of Medicine at Mount Sinai | ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF |
| JP2023502650A (ja) | 2019-11-18 | 2023-01-25 | セキラス ピーティーワイ リミテッド | 遺伝子再集合インフルエンザウイルスを産生するための方法 |
| US12485166B2 (en) | 2020-02-06 | 2025-12-02 | Longhorn Vaccines And Diagnostics, Llc | Vaccines for the treatment and prevention of zoonotic infections |
| RU2754398C1 (ru) * | 2020-06-25 | 2021-09-01 | Общество с ограниченной ответственностью «ФОРТ» | Способ получения четырехвалентной вакцины для профилактики гриппа |
| CN116171166A (zh) | 2020-06-30 | 2023-05-26 | 塞其里斯英国有限公司 | 水包油乳液佐剂的冷过滤 |
| KR20230091978A (ko) | 2020-10-20 | 2023-06-23 | 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 | 면역원성 항원 |
| WO2025019631A1 (en) | 2023-07-19 | 2025-01-23 | Icahn School Of Medicine At Mount Sinai | Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5520A (en) | 1848-04-18 | Oegan-pipb | ||
| US639A (en) | 1838-03-17 | of boston | ||
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| DD155875A1 (de) | 1980-12-31 | 1982-07-14 | Willy Nordheim | Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| DD211444A3 (de) | 1982-08-19 | 1984-07-11 | Saechsisches Serumwerk | Verfahren zur herstellung von influenza-impfstoffen |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| DD300833A7 (de) | 1985-10-28 | 1992-08-13 | Saechsische Landesgewerbefoerd | Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| NO902352L (no) * | 1989-05-29 | 1990-11-30 | Lion Corp | Fremgangsmaate for fremstilling av en vaksine mot dental karies, samt vaksineblandinger for anvendelse som nesedraaper |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| JP3723231B2 (ja) | 1991-12-23 | 2005-12-07 | ディミナコ アクチェンゲゼルシャフト | アジュバント |
| IL101007A (en) * | 1992-02-18 | 1997-08-14 | Pharmos Ltd | Dry stable compositions prepared by lyophilization |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| ATE157882T1 (de) | 1993-03-23 | 1997-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5616487A (en) * | 1994-09-15 | 1997-04-01 | Aastrom Biosciences, Inc. | Stabilized retrovirus compositions |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| ATE214603T1 (de) * | 1995-06-30 | 2002-04-15 | American Cyanamid Co | Stabile makrolide und makrolide imptstoff- zusammensetzungen |
| US20020165168A1 (en) | 1995-12-16 | 2002-11-07 | Joachim Bunger | Use of sugar derivatives as antimicrobial, antimycotic and/or antiviral active substances |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| US5919480A (en) * | 1996-06-24 | 1999-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal influenza vaccine composition and method |
| US6403098B1 (en) * | 1996-09-26 | 2002-06-11 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| DE19649895A1 (de) * | 1996-12-02 | 1998-06-04 | Henkel Kgaa | Schäumende Körperreinigungsmittel |
| WO1998030228A1 (en) | 1997-01-13 | 1998-07-16 | Emory University | Compounds and their combinations for the treatment of influenza infection |
| GB9705740D0 (en) * | 1997-03-20 | 1997-05-07 | Medeva Europ Ltd | A method of preservation |
| NZ338101A (en) | 1997-04-01 | 2002-03-28 | Corixa Corp | Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| GB9711990D0 (en) * | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| ES2298316T3 (es) * | 1997-09-05 | 2008-05-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| IL138000A0 (en) | 1998-04-09 | 2001-10-31 | Smithkline Beecham Biolog | Adjuvant compositions |
| FR2780278B1 (fr) * | 1998-06-24 | 2001-01-19 | Oreal | Composition conditionnante et detergente et utilisation |
| DE19841796A1 (de) * | 1998-09-12 | 2000-03-16 | Beiersdorf Ag | Kombinationen von Antiadhäsiva (Kohlenhydrate) und Mikrobiziden |
| DE60014076T2 (de) * | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
| AUPQ233799A0 (en) * | 1999-08-19 | 1999-09-09 | Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales | Recombinant sub-unit vaccine |
| TR200200776T2 (tr) * | 1999-09-24 | 2002-06-21 | Smithkline Beecham Biologicals S.A. | Burun içi grip virüsü aşısı. |
| KR20020048942A (ko) * | 1999-09-24 | 2002-06-24 | 장 스테판느 | 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트 |
| CZ20021043A3 (cs) * | 1999-09-24 | 2002-08-14 | Smithkline Beecham Biologicals S. A. | Pouľití kombinace polyoxyethylensorbitanového esteru a oktoxynolu pro výrobu pomocného prostředku |
| US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
| CA2382985A1 (en) * | 1999-10-19 | 2001-04-26 | Jeffrey Michael Morgan | Antimicrobial compositions comprising pyroglutamic acid and optionally metal salts |
| KR20030055275A (ko) | 2000-10-02 | 2003-07-02 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 분할 외피 바이러스 제조물 |
| JP2004536785A (ja) * | 2001-02-23 | 2004-12-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規なワクチン |
| TWI228420B (en) * | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| US9856414B2 (en) | 2013-06-10 | 2018-01-02 | Dober Chemical Corp. | Compositions, systems and methods of making coated additive components |
-
2002
- 2002-05-28 TW TW091111304A patent/TWI228420B/zh not_active IP Right Cessation
- 2002-05-28 MY MYPI20021956A patent/MY134424A/en unknown
- 2002-05-29 DK DK02743125T patent/DK1407008T3/da active
- 2002-05-29 EP EP12170561A patent/EP2495314A1/en not_active Withdrawn
- 2002-05-29 PL PL366990A patent/PL206435B1/pl unknown
- 2002-05-29 US US10/480,952 patent/US7316813B2/en not_active Expired - Lifetime
- 2002-05-29 PT PT02743125T patent/PT1407008E/pt unknown
- 2002-05-29 WO PCT/EP2002/005883 patent/WO2002097072A2/en not_active Ceased
- 2002-05-29 JP JP2003500240A patent/JP4074582B2/ja not_active Expired - Lifetime
- 2002-05-29 CA CA2448208A patent/CA2448208C/en not_active Expired - Lifetime
- 2002-05-29 BR BRPI0210076 patent/BRPI0210076B8/pt not_active IP Right Cessation
- 2002-05-29 DE DE60230760T patent/DE60230760D1/de not_active Expired - Lifetime
- 2002-05-29 AU AU2006200742A patent/AU2006200742C9/en active Active
- 2002-05-29 EP EP09100013A patent/EP2039761A1/en not_active Ceased
- 2002-05-29 ES ES02743125T patent/ES2318020T3/es not_active Expired - Lifetime
- 2002-05-29 CN CNB028146557A patent/CN1279165C/zh not_active Expired - Lifetime
- 2002-05-29 HU HU0400445A patent/HU229368B1/hu unknown
- 2002-05-29 MX MXPA03010944A patent/MXPA03010944A/es active IP Right Grant
- 2002-05-29 AT AT02743125T patent/ATE420159T1/de active
- 2002-05-29 CZ CZ20033253A patent/CZ298697B6/cs unknown
- 2002-05-29 AU AU2002344182A patent/AU2002344182C1/en not_active Expired
- 2002-05-29 SI SI200230806T patent/SI1407008T1/sl unknown
- 2002-05-29 KR KR1020037015649A patent/KR100871021B1/ko not_active Expired - Lifetime
- 2002-05-29 CN CN2006101156101A patent/CN101069744B/zh not_active Expired - Lifetime
- 2002-05-29 EP EP02743125A patent/EP1407008B1/en not_active Expired - Lifetime
- 2002-05-29 NZ NZ529755A patent/NZ529755A/en not_active IP Right Cessation
- 2002-05-30 AR ARP020102018A patent/AR036039A1/es not_active Application Discontinuation
-
2003
- 2003-11-18 IL IL158931A patent/IL158931A/en active IP Right Grant
- 2003-11-24 NO NO20035208A patent/NO335212B1/no not_active IP Right Cessation
- 2003-11-27 CO CO03104769A patent/CO5540349A2/es active IP Right Grant
- 2003-11-27 ZA ZA2003/09250A patent/ZA200309250B/en unknown
-
2007
- 2007-10-18 US US11/874,647 patent/US20080181914A1/en not_active Abandoned
-
2008
- 2008-01-17 IL IL188834A patent/IL188834A/en active IP Right Grant
-
2009
- 2009-03-26 CY CY20091100357T patent/CY1108930T1/el unknown
-
2013
- 2013-12-18 FR FR13C0072C patent/FR13C0072I1/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0210076B8 (pt) | preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato | |
| ES2357752T3 (es) | Reducción de riesgos latrogénicos potenciales asocidos con vacunas. | |
| BR112022024248A2 (pt) | Vacinas de combinação à base de ácido nucleico | |
| BR9911163A (pt) | Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo | |
| Johansson | Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine | |
| JP2004527264A5 (https=) | ||
| ES2377761T3 (es) | Vacuna contra la gripe de emulsión de aceite en agua | |
| BR0014281A (pt) | Vacina contra vìrus de gripe intranasal | |
| BR0113822A (pt) | Vacina | |
| BRPI0208183B8 (pt) | peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer | |
| ES2553113T3 (es) | Vacuna | |
| ES2552383T3 (es) | Regímenes de vacuna de la gripe para cepas asociadas a pandemias | |
| BRPI0707300A8 (pt) | Vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica | |
| BR9801015A (pt) | Vacina de antìgeno de superfìcie contra gripe, e, processo para a preparação de proteìnas de antìgeno de superfìcie de vìrus de gripe preparados em uma cultura de célula animal. | |
| BR0312474A (pt) | Partìcula viral adjuvante | |
| BR0208301A (pt) | Vacinas de ácido nucléico para prevenção de infecção por flavivìrus | |
| BR0205684A (pt) | Compostos cìclicos fundidos e seu uso medicinal | |
| BR0207067A (pt) | Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo | |
| NO985821L (no) | Substituerte syklopentanforbindelser som er nyttige som neuraminidaseinhibitorer | |
| de Bruijn et al. | Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly | |
| BRPI0511776A (pt) | vìrus atenuado de influenza de suìnos, formulação imunogênica, formulação farmacêutica, métodos para imunizar ou induzir uma resposta imune em um porco, para tratar uma infecção por vìrus de influenza de suìnos em um porco, para tratar cáncer em um porco, e para produzir uma formulação imunogênica, célula, linhagem de células de porco, e, ovo embrionado | |
| BR112022017923A2 (pt) | Tratamento de infecção por coronavírus | |
| NZ592713A (en) | Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9 | |
| BR0112497A (pt) | Antìgenos de streptococcus pyogenes | |
| Baldwin et al. | Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 7/04 Ipc: C12N 7/04 (2006.01), A61K 39/145 (2006.01), A61P 3 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: GLAXOSMITHKLINE BIOLOGICALS BRANCH OF SMITHKLINE B |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/01/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 29/05/2022 |